NEW YORK – Veracyte's planned acquisition of precision oncology firm Decipher Biosciences for $600 million in cash and stock, announced on Wednesday, should help the firm expand its global reach into the cancer diagnostic space using its nCounter platform.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.